A Network Analysis of Drug Combinations Associated with Acute Generalized Exanthematous Pustulosis (AGEP)

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Oct 13

PMID 34640505

Citations 2

Authors

Adrian Martinez-De la Torre

Eva van Weenen

Mathias Kraus

Stefan Weiler

Stefan Feuerriegel

Andrea M Burden

Affiliations

Soon will be listed here.

Abstract

Acute generalized exanthematous pustulosis (AGEP) is a rare skin adverse drug reaction. The pathophysiology and causative drugs associated with AGEP are poorly understood, with the majority of studies in AGEP focusing on a single-drug-outcome association. We therefore aimed to explore and characterize frequently reported drug combinations associated with AGEP using the WHO pharmacovigilance database VigiBase. In this explorative cross-sectional study of a pharmacovigilance database using a data-driven approach, we assessed individual case safety reports (ICSR) with two or more drugs reported to VigiBase. A total of 2649 ICSRs reported two or more drugs. Cardiovascular drugs, including antithrombotics and beta-blockers, were frequently reported in combination with other drugs, particularly antibiotics. The drug pair of amoxicillin and furosemide was reported in 57 ICSRs (2.2%), with an O/E ratio of 1.3, and the combination of bisoprolol and furosemide was recorded 44 times (1.7%), with an O/E ratio of 5.5. The network analysis identified 10 different communities of varying sizes. The largest cluster primarily consisted of cardiovascular drugs. This data-driven and exploratory study provides the largest real-world assessment of drugs associated with AGEP to date. The results identify a high frequency of cardiovascular drugs, particularly used in combination with antibiotics.

Citing Articles

Relationships between acute generalized eruptive pustulosis, age, sex, primary disease, and prescription medications: Further analysis of the Japanese Adverse Drug Event Report database.

Yamashita M, Maezawa M, Wakabayashi W, Hirofuji S, Miyasaka K, Ichihara N Heliyon. 2024; 10(7):e27800.

PMID: 38560160 PMC: 10979194. DOI: 10.1016/j.heliyon.2024.e27800.

Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients.

Vallejo-Yague E, Martinez-De la Torre A, Mohamad O, Sabu S, Burden A J Clin Med. 2022; 11(2).

PMID: 35054090 PMC: 8780223. DOI: 10.3390/jcm11020397.

References

Duman H, Topal I, Kocaturk E, Cure K, Mansuroglu I . Acute generalized exanthematous pustulosis induced by hydroxychloroquine: a case with atypical clinical presentation. An Bras Dermatol. 2017; 92(3):404-406. PMC: 5514588. DOI: 10.1590/abd1806-4841.20175561. View

Cheng F, Kovacs I, Barabasi A . Network-based prediction of drug combinations. Nat Commun. 2019; 10(1):1197. PMC: 6416394. DOI: 10.1038/s41467-019-09186-x. View

Newman M . Finding community structure in networks using the eigenvectors of matrices. Phys Rev E Stat Nonlin Soft Matter Phys. 2006; 74(3 Pt 2):036104. DOI: 10.1103/PhysRevE.74.036104. View

Sidoroff A, Dunant A, Viboud C, Halevy S, Bouwes Bavinck J, Naldi L . Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007; 157(5):989-96. DOI: 10.1111/j.1365-2133.2007.08156.x. View

Belhadjali H, Mandhouj S, Moussa A, Njim L, Amri M, Zakhama A . Mercury-induced acute generalized exanthematous pustulosis misdiagnosed as a drug-related case. Contact Dermatitis. 2008; 59(1):52-4. DOI: 10.1111/j.1600-0536.2007.01306.x. View

Feldmeyer L, Heidemeyer K, Yawalkar N . Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy. Int J Mol Sci. 2016; 17(8). PMC: 5000612. DOI: 10.3390/ijms17081214. View

Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M . A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2012; 168(3):555-62. DOI: 10.1111/bjd.12125. View

Ameur K, Youssef M, Belhadjali H, Soua Y, Korbi M, Henchi M . Occupational acute generalized exanthematous pustulosis induced by disperse dyes in a textile. Contact Dermatitis. 2019; 80(6):411-412. DOI: 10.1111/cod.13241. View

Schafer I, Kaduszkiewicz H, Wagner H, Schon G, Scherer M, Bussche H . Reducing complexity: a visualisation of multimorbidity by combining disease clusters and triads. BMC Public Health. 2014; 14:1285. PMC: 4301832. DOI: 10.1186/1471-2458-14-1285. View

10.

Botsis T, Ball R . Network analysis of possible anaphylaxis cases reported to the US vaccine adverse event reporting system after H1N1 influenza vaccine. Stud Health Technol Inform. 2011; 169:564-8. View

11.

Bostan E, Yalcin H, Akdogan N, Ozdemir D, Karaduman A . Acute generalized exanthematous pustulosis induced by iron carboxymaltose infusion: A case report. Dermatol Ther. 2020; 33(3):e13445. DOI: 10.1111/dth.13445. View

12.

Davazdahemami B, Delen D . A chronological pharmacovigilance network analytics approach for predicting adverse drug events. J Am Med Inform Assoc. 2018; 25(10):1311-1321. PMC: 7646912. DOI: 10.1093/jamia/ocy097. View

13.

Sidoroff A, Halevy S, Bavinck J, Vaillant L, Roujeau J . Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol. 2001; 28(3):113-9. DOI: 10.1034/j.1600-0560.2001.028003113.x. View

14.

Libby P, Lichtman A, Hansson G . Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity. 2013; 38(6):1092-104. PMC: 3764500. DOI: 10.1016/j.immuni.2013.06.009. View

15.

Paolino A, Walsh S, Basu T, Creamer D . Severe drug-induced kidney injury in acute generalized exanthematous pustulosis. Clin Exp Dermatol. 2017; 43(3):323-324. DOI: 10.1111/ced.13316. View

16.

Burkhart K, Abernethy D, Jackson D . Data Mining FAERS to Analyze Molecular Targets of Drugs Highly Associated with Stevens-Johnson Syndrome. J Med Toxicol. 2015; 11(2):265-73. PMC: 4469729. DOI: 10.1007/s13181-015-0472-1. View

17.

Rader D, Daugherty A . Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008; 451(7181):904-13. DOI: 10.1038/nature06796. View

18.

Smeets T, Jessurun N, Harmark L, Kardaun S . Clindamycin-induced acute generalised exanthematous pustulosis: five cases and a review of the literature. Neth J Med. 2016; 74(10):421-428. View

19.

Zheng J, Gao Y, Yi X, Ding Y . A Case of Ceftriaxone-Induced Acute Generalized Exanthematous Pustulosis/Generalized Pustular Psoriasis Overlap. Case Rep Dermatol. 2018; 10(1):69-75. PMC: 5903148. DOI: 10.1159/000488076. View

20.

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007; 147(8):573-7. DOI: 10.7326/0003-4819-147-8-200710160-00010. View